SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

TYRIAN DIAGNOSTICS LIMITED (TDX)

Former Name ASX

SHARE PRICES

Former (or subsequent) names

Shareholder links

Our website ranking of TDX: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Link Market Services, Rhodes Corporate Park, 1A Homebush Bay Drive, Rhodes NSW 2138

Tel : +61 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

Address: Unit 1, 35-41 Waterloo Road, NORTH RYDE, NSW, AUSTRALIA, 2113
Tel:  (02) 9889 1830 Fax: (02) 9889 1805

Date first listed: 30/09/2004
Company Secretary: Mr Andrew Blunden
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Principal Activities: development and commercialisation of diagnostic and therapeutic products in the areas of respiratory disease, neurobiology & aging and cancer

name changed to Contango Asset Management Limited

08/09/2016

we understand that on or about this date the company consolidated its shares 1 for 300

06/09/2016

The lodged replacement prospectus is for a public offering of 28,643,300 Shares (post Share Consolidation) at an Offer Price of $0.60 each to raise $17,185,980.

31/08/2016

The company advises that it has lodged a replacement prospectus with ASIC dated 31 August 2016 which replaces the original prospectus lodged on 18 August 2016.

31/08/2016

The company releases the results of its meeting.

25/08/2016

The company releases the chairman's address to shareholders at extraordinary general meeting.

25/08/2016

The company announces that it has today lodged its prospectus dated 18 August 2016 with ASIC for a public offer of 28,643,000 Shares (post share consolidation) at an offer price of $0.60 (post share consolidation) each to raise $17,185,980 (Offer). This Prospectus is issued for the purpose of also re-complying with the admission requirements under Chapters 1 and 2 of the ASX Listing Rules following a change to the nature and scale of the Company's activities.

18/08/2016

The company lodges its Preliminary final report for the year ending 30 June 2016.

18/08/2016

Shareholders get 1 share for every 300 they presently hold.

26/07/2016

Notice is given that an extraordinary meeting will be held at 9:00 AM (AEST) on Thursday, 25 August 2016, at the offices of K&L Gates, Level 31, 1 O'Connell Street, Sydney NSW 2000.

26/07/2016

The company lodges its quarterly report.

18/07/2016

The securities of Tyrian Diagnostics Limited will be suspended from quotation immediately, following receipt of an announcement regarding its proposed change of activities. The Company's securities will remain suspended until the Company has complied with Chapters 1 and 2 of the Listing Rules in accordance with Listing Rule 11.1.3.

24/06/2016

the suspension of trading in the securities of Tyrian Diagnostics Limited (the "Company") will be lifted from the commencement of trading on Thursday, 18 November 2010, in accordance with listing rule 17.7, following an announcement by the Company in relation to a capital raising

18/11/2010

the securities of Tyrian Diagnostics Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending an announcement with regard to a proposed capital raising

17/11/2010

name changed from Proteome Systems Limited

19/11/2008

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

     

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Roger AmosChairman18/06/2007
    George BoubourasManaging Director25/08/2016
    Andrew BlundenCFO24/02/2012
    Martin SwitzerNon Exec Director25/08/2016
    Charlie AitkenNon Exec Director25/08/2016

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Simon O'LoughlinNon Exec Director23/02/201625/08/2016
    Merilyn SleighNon Exec Director28/11/200825/08/2016
    Caroline PopperNon Exec Director12/12/200723/02/2016
    Jenny HarryCEO, Director09/03/200524/02/2012
    Lisa JonesGeneral Counsel01/08/200424/02/2012
    Michael VamosCFO02/02/201024/11/2011

    Date of first appointment, title may have changed.